BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38723231)

  • 21. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma.
    Preis M; Gardner TB; Gordon SR; Pipas JM; Mackenzie TA; Klein EE; Longnecker DS; Gutmann EJ; Sempere LF; Korc M
    Clin Cancer Res; 2011 Sep; 17(17):5812-21. PubMed ID: 21652542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
    Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
    JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling.
    Hirono S; Yamaue H; Hoshikawa Y; Ina S; Tani M; Kawai M; Ushijima M; Matsuura M; Saiki Y; Saiura A; Yamamoto J; Miki Y; Noda T
    Cancer Sci; 2010 Jan; 101(1):259-66. PubMed ID: 19817750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.
    Birnbaum DJ; Begg SKS; Finetti P; Vanderburg C; Kulkarni AS; Neyaz A; Hank T; Tai E; Deshpande V; Bertucci F; Birnbaum D; Lillemoe KD; Warshaw AL; Mino-Kenudson M; Fernandez-Del Castillo C; Ting DT; Liss AS
    Clin Cancer Res; 2021 Apr; 27(8):2314-2325. PubMed ID: 33547202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.
    Jandaghi P; Najafabadi HS; Bauer AS; Papadakis AI; Fassan M; Hall A; Monast A; von Knebel Doeberitz M; Neoptolemos JP; Costello E; Greenhalf W; Scarpa A; Sipos B; Auld D; Lathrop M; Park M; Büchler MW; Strobel O; Hackert T; Giese NA; Zogopoulos G; Sangwan V; Huang S; Riazalhosseini Y; Hoheisel JD
    Gastroenterology; 2016 Dec; 151(6):1218-1231. PubMed ID: 27578530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
    Luchini C; Paolino G; Mattiolo P; Piredda ML; Cavaliere A; Gaule M; Melisi D; Salvia R; Malleo G; Shin JI; Cargnin S; Terrazzino S; Lawlor RT; Milella M; Scarpa A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):227. PubMed ID: 33115526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
    Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
    Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
    J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
    BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Zhu L; Wang X
    Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32024063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma.
    Xiao Y; Zhang B; Cloyd JM; Xu G; Du S; Mao Y; Pawlik TM
    Surg Oncol; 2022 Sep; 44():101849. PubMed ID: 36116415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
    Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
    Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
    Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
    Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
    Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.
    Park JK; Jeong HO; Kim H; Choi JH; Lee EM; Kim S; Jang J; Choi DW; Lee SH; Kim KM; Jang KT; Lee KH; Lee KT; Lee MW; Lee JK; Lee S
    Mol Cancer; 2024 May; 23(1):87. PubMed ID: 38702773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
    Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
    Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.